

Publications by CR&T-Funded Researchers

Publications are continually being updated,
check back often for updates.



Abu-Zeinah, G., Erdos, K., Lee, N., Lebbe, A., Bouhali, I., Khalid, M., **Silver, R., & Scandura, J.**, Are thrombosis, progression, and survival in ET predictable?. *Blood Cancer J.* **14**, 103 (2024). <https://doi.org/10.1038/s41408-024-01079-7>

Reem S. Chamseddine, Oleksandr Savenkov, Shehroz Rana, Mohammed Khalid, **Richard T. Silver**, Nicole Kucine, **Joseph M. Scandura, Ghaith Abu-Zeinah**; Cytoreductive therapy in younger adults with polycythemia vera: a meta-analysis of safety and outcomes. *Blood Adv* 2024; 8 (10): 2520–2526. doi: <https://doi.org/10.1182/bloodadvances.2023012459>

Izzo F, Myers RM, Ganesan S, Mekerishvili L, Kottapalli S, Prieto T, Eton EO, Botella T, Dunbar AJ, Bowman RL, Sotelo J, Potenski C, Mimitou EP, Stahl M, El Ghaity-Beckley S, Arandela J, Raviram R, Choi DC, Hoffman R, Chaligné R, Abdel-Wahab O, Smibert P, Ghobrial IM, **Scandura JM**, Marcellino B, Levine RL, Landau DA., Mapping genotypes to chromatin accessibility profiles in single cells. *Nature* **629**, 1149–1157 (2024). <https://doi.org/10.1038/s41586-024-07388-y>

Silver, R.T., Erdos, K., Taylor, E. *et al.* Splenomegaly (SPML) in polycythemia vera (PV): its clinical significance and its relation to symptoms, post-polycythemic myelofibrosis (PPMF) and survival. *Leukemia* **37**, 691–694 (2023). <https://doi.org/10.1038/s41375-022-01793-w>

Silver, R. T., & Abu-Zeinah, G. (2023). Polycythemia vera: aspects of its current diagnosis and initial treatment. *Expert Review of Hematology*, *16*(4), 253–266. <https://doi.org/10.1080/17474086.2023.2198698>

Mora B, Maffioli M, Rumi E, Guglielmelli P, Caramella M, Kuykendall A, et al. Incidence of blast phase in myelofibrosis according to anemia severity. *eJHaem.* 2023; 4: 679–689. <https://doi.org/10.1002/jha2.745>

Abu-Zeinah, G., Tokumori, F. G., Erdos, K., Bouhali, I., Choi, D., Silver, R., Scandura J.; Polycythemia Vera Patients with >20% Reduction in Whole Blood *JAK2*^{V617F} Allele Frequency Have Improved Myelofibrosis-Free Survival but Not Overall Survival. *Blood* 2022; 140 (Supplement 1): 6819–6820. doi: <https://doi.org/10.1182/blood-2022-168283>

Choi, D., **Abu-Zeinah, G.,** Di Giandomenico, S., **Erdos, K., Scandura J.;** *JAK2*^{V617F} Impairs T Cell Differentiation in Polycythemia Vera. *Blood* 2022; 140 (Supplement 1): 6746–6747. doi: <https://doi.org/10.1182/blood-2022-167785>

Reem S. Chamseddine, Shehroz Rana, Mohammed Khalid, Nicole Kucine, **Richard T. Silver, Joseph Scandura, Ghaith Abu-Zeinah;** Safety of Cytoreductive Therapy in Younger Patients with Polycythemia Vera: A Systematic Review and Meta-Analysis. *Blood* 2022; 140 (Supplement 1): 3999–4000. doi: <https://doi.org/10.1182/blood-2022-168014>

Franco Castillo Tokumori, **Joseph Scandura, Ghaith Abu-Zeinah;** Polycythemia Vera Molecular Response and Its Correlation with Disease Progression: A Systematic Review and Meta-Analysis. *Blood* 2022; 140 (Supplement 1): 3993–3994. doi: <https://doi.org/10.1182/blood-2022-170731>

Ghaith Abu-Zeinah, Spencer Krichevsky, **Katie Erdos, Richard T. Silver, Joseph Scandura;** Unbiased Identification of Thrombosis Risk Factors in Polycythemia Vera (PV) Using Machine Learning and Rich Data from Automated Extraction of Medical Records Generates Dynamic Models Highly Predictive for Thrombosis in PV. *Blood* 2022; 140 (Supplement 1): 3961–3962. doi: <https://doi.org/10.1182/blood-2022-170893>